Amylin Agonists: A Novel Approach in the Treatment of Diabetes
Authors:
- 1 December 2004
- journal article
- review article
- Published by American Diabetes Association in Diabetes
- Vol. 53 (suppl_3) , S233-S238
Abstract
Amylin is a peptide hormone that is cosecreted with insulin from the pancreatic β-cell and is thus deficient in diabetic people. It inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent. Amylin replacement could therefore possibly improve glycemic control in some people with diabetes. However, human amylin exhibits physicochemical properties predisposing the peptide hormone to aggregate and form amyloid fibers, which may play a part in β-cell destruction in type 2 diabetes. This obviously makes it unsuitable for pharmacological use. A stable analog, pramlintide, which has actions and pharmacokinetic and pharmacodynamic properties similar to the native peptide, has been developed. The efficacy and safety of pramlintide administration has been tested in a vast number of clinical trials. Aproximately 5,000 insulin-treated patients have received pramlintide and ∼250 for ≥2 years. The aims of this review are to 1) briefly describe actions of amylin as demonstrated in animal and human models and 2) primarily review results from clinical trials with the amylin analog pramlintide.Keywords
This publication has 68 references indexed in Scilit:
- The Human Amylin Analog, Pramlintide, Reduces Postprandial Hyperglucagonemia in Patients with Type 2 Diabetes MellitusHormone and Metabolic Research, 2002
- Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivityDiabetes/Metabolism Research and Reviews, 2002
- Identification of a novel human islet amyloid polypeptide β-sheet domain and factors influencing fibrillogenesisJournal of Molecular Biology, 2001
- Insulin lispro (Lys(B28), Pro(B29)) in the treatment of diabetes during the fasting month of RamadanDiabetic Medicine, 1999
- Plasma Amylin Immunoreactivity and Insulin Resistance in Insulin Resistant Relatives of Patients with Non-Insulin-Dependent Diabetes MellitusHormone and Metabolic Research, 1998
- Hypoglycemia overrides amylin-mediated regulation of gastric emptying in ratsDiabetes, 1998
- Pramlintide: A Human Amylin Analogue Reduced Postprandial Plasma Glucose, Insulin, and C-peptide Concentrations in Patients with Type 2 DiabetesDiabetic Medicine, 1997
- Pharmacokinetics and Pharmacodynamics of AC137 (25,28,29 Tripro‐Amylin, Human) After Intravenous Bolus and Infusion Doses in Patients with Insulin‐Dependent DiabetesThe Journal of Clinical Pharmacology, 1996
- Reduction of Postprandial Hyperglycemia in Subjects With IDDM by Intravenous Infusion of AC137, a Human Amylin AnalogueDiabetes Care, 1995
- Daily amylin replacement reverses hepatic glycogen depletion in insulin‐treated streptozotocin diabetic ratsFEBS Letters, 1991